oral semaglutide launch The U.S. Food and Drug Administration approved Novo Nordisk's (Wegovy) as the first GLP-1 pill for obesity and cardiovascular risk reduction, with the company targeting an early 2026 launch. Novo Semaglutide Oral
Pay in 4 interest-free payments of $6.01 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31






.jpg)
















